Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

被引：1

作者：

Akula, Vinita ^{[1
]}

Chen, Lily ^{[1
]}

Acikgoz, Yusuf ^{[2
]}

Klein, Katherine ^{[1
]}

Yavuz, Betul Gok ^{[3
]}

Cevik, Lokman ^{[4
]}

Demir, Tarik ^{[5
]}

Manne, Ashish ^{[2
]}

Sahin, Ilyas ^{[6
]}

Kaseb, Ahmed ^{[7
]}

Hasanov, Elshad ^{[2
]}

机构：

[1] Univ Texas, Dept Internal Med, Hlth Sci Ctr, Houston UTHealth, Houston, TX USA

[2] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA

[3] Univ Missouri, Dept Med, Columbia, MO USA

[4] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH USA

[5] Northwestern Univ, Div Hematol & Oncol Dev Therapeut Inst, Chicago, IL USA

[6] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA

[7] Univ Texas, Dept Gastrointestinal Med Oncol, MD Anderson Canc Ctr, Houston, TX USA

来源：

NPJ PRECISION ONCOLOGY | 2025年 / 9卷 / 01期

关键词：

CAMRELIZUMAB PLUS APATINIB; OPEN-LABEL; DOUBLE-BLIND; SINGLE-ARM; RECURRENCE; RESECTION; SORAFENIB; CANCER; TRIAL; HCC;

D O I：

10.1038/s41698-025-00846-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

引用

页数：13

共 50 条

[41] Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
Huang, Xiaozhun
Xu, Lin
Ma, Teng
Yin, Xin
Huang, Zhangkan
Ran, Yihong
Ni, Yong
Bi, Xinyu
Che, Xu
FRONTIERS IN ONCOLOGY, 2021, 11
[42] Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
Zhu, Andrew X.
Lin, Yong
Ferry, David
Widau, Ryan C.
Saha, Abhijoy
IMMUNOTHERAPY, 2022, 14 (16) : 1341 - 1351
[43] Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma A Meta-analysis
Jacome, Alexandre A.
Castro, Ana Carolina G.
Vasconcelos, Joao Paulo S.
Silva, Maria Helena C. R.
Lessa, Marco Antonio O.
Moraes, Eduardo D.
Andrade, Aline C.
Lima, Frederico M. T.
Farias, Joao Paulo F.
Gil, Roberto A.
Prolla, Gabriel
Garicochea, Bernardo
JAMA NETWORK OPEN, 2021, 4 (12) : E2136128
[44] Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
Abenavoli, Ludovico
Montori, Michele
Baroni, Gianluca Svegliati
Argenziano, Maria Eva
Giorgi, Francesca
Scarlata, Giuseppe Guido Maria
Ponziani, Francesca
Scarpellini, Emidio
MEDICINA-LITHUANIA, 2023, 59 (08):
[45] Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, Bruno
Chan, Stephen L.
Meyer, Tim
Reig, Maria
El-Khoueiry, Anthony
Galle, Peter R.
JOURNAL OF HEPATOLOGY, 2020, 72 (02) : 320 - 341
[46] Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma
Chen, Xiu
Kou, Liqiu
Xie, Xiaolu
Su, Song
Li, Jun
Li, Yaling
IMMUNOLOGY, 2024, 172 (01) : 21 - 45
[47] Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Liu, Tong
Meng, Guorui
Ma, Shihui
You, Junqi
Yu, Liang
He, Risheng
Zhao, Xudong
Cui, Yunfu
FRONTIERS IN IMMUNOLOGY, 2024, 15
[48] Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma
Muhammed, Ambreen
D'Alessio, Antonio
Enica, Andrei
Talbot, Thomas
Fulgenzi, Claudia Angela Maria
Nteliopoulos, Georgios
Goldin, Robert D.
Cortellini, Alessio
Pinato, David J.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2022, 22 (03) : 253 - 264
[49] Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma
Rizzo, Alessandro
Ricci, Angela Dalia
Brandi, Giovanni
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2022, 7 (01): : 1 - 3
[50] Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle
Sukowati, Caecilia
Cabral, Loraine Kay D.
Tiribelli, Claudio
ANNALS OF HEPATOLOGY, 2022, 27 (05)

← 1 2 3 4 5 →